Bristol-Myers Squibb Option Alert: Jan 16 $55 Puts at the Bid: 1000 vs 2166 OI

Bristol-Myers Squibb Option Alert: Jan 16 $55 Puts at the Bid: 1000 @ $5.5 vs 2166 OI; Ref=$54.76

Bristol-Myers Squibb (NYSE:BMY) 주식

Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

SWKS

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 개선되었음을 보여 주었으나, 목요일에 여전히 &#34;공포&#34; 영역에 머물렀다. 미국 증시는 목요일(6일)에 혼조세를 보였으며, S&amp;P 500 지수는 3거래일 연속 상승했다. 

S&amp;P 500 지수 3거래일 연속 상승: 투자 심리 개선, 탐욕 지수는 여전히 &#39;공포&#39; 영역에

AMZN

NVDA

CNN 머니 공포·탐욕 지수는 전체 시장 심리에서 개선을 나타냈지만, 수요일에는 여전히 &#34;공포&#34; 영역에 머물렀다. 수요일(5일) 미국 증시는 상승 마감했고 특히 다우존스 지수는 300포인트 이상 올랐다.

엔비디아 급등, 다우 지수 300p 이상 상승: 투자 심리 개선되었지만 탐욕 지수는 여전히 &#39;공포&#39; 영역

목요일(6일) 아침 미국 주식 선물이 상승하는 가운데 오늘 투자자들의 주목을 받을 수 있는 주식들은 다음과 같다. 브리스톨-마이어스, 포드, 아마존, Arm 홀딩스 및 하니웰

목요일 주목해야 할 주식: 브리스톨-마이어스, 포드, 아마존, Arm 홀딩스 및 하니웰

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb Co

BRISTOL-MYERS SQUIBB $2PR by Bristol-Myers Squibb Co.

Investors with a lot of money to spend have taken a bearish stance on Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BMY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 32 uncommon options trades for Bristol-Myers Squibb.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 46%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $768,961, and 27 are calls, for a total amount of $2,021,345.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $25.0 to $70.0 for Bristol-Myers Squibb during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Bristol-Myers Squibb's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers Squibb's whale activity within a strike price range from $25.0 to $70.0 in the last 30 days. 
<h3>Bristol-Myers Squibb Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741378568_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$4.85</td>
<td>$4.65</td>
<td>$4.75</td>
<td>$60.00</td>
<td>$855.0K</td>
<td>12.4K</td>
<td>2.2K</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.25</td>
<td>$1.05</td>
<td>$1.2</td>
<td>$62.50</td>
<td>$240.0K</td>
<td>386</td>
<td>31</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.2</td>
<td>$9.1</td>
<td>$9.2</td>
<td>$70.00</td>
<td>$227.2K</td>
<td>2</td>
<td>248</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$13.5</td>
<td>$11.5</td>
<td>$11.65</td>
<td>$67.50</td>
<td>$226.0K</td>
<td>0</td>
<td>194</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$15.5</td>
<td>$13.3</td>
<td>$14.22</td>
<td>$52.50</td>
<td>$123.7K</td>
<td>602</td>
<td>87</td>
</tr>
</tbody>
</table>

<h3>About Bristol-Myers Squibb</h3>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
After a thorough review of the options trading surrounding Bristol-Myers Squibb, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Bristol-Myers Squibb</h3>
<ul>
<li>With a volume of 13,248,550, the price of BMY is up 1.71% at $61.21. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 48 days.</li>
</ul>
<h3>Expert Opinions on Bristol-Myers Squibb</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $62.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on Bristol-Myers Squibb with a target price of $62. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Bristol-Myers Squibb, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Market Whales and Their Recent Bets on BMY Options

On Friday, the European Commission (EC) approved Bristol Myers Squibb &amp; Co&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo&nbsp;(nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced <a target="_blank" href="https://www.benzinga.com/news/large-cap" rel="noreferrer noopener">hepatocellular carcinoma (HCC)</a>, a type of liver cancer.
The decision is based on results from the CheckMate -9DW study. Results showed that dual immunotherapy treatment with&nbsp;Opdivo&nbsp;plus&nbsp;Yervoy&nbsp;led to a statistically significant and clinically meaningful improvement in overall survival (OS), the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44187439/bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-plus-yervoy-ipilim" rel="noreferrer noopener">trial&#8217;s primary endpoint</a>.
In the trial, 85% of patients in the comparator arm were treated with lenvatinib and 15% with sorafenib.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44148320/bristol-myers-acquired-myokardia-drops-fulcrum-agreement-ending-cardiomyopathy-research-deal" rel="noreferrer noopener">Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal</a>
The median OS was 23.7 months for&nbsp;Opdivo&nbsp;plus&nbsp;Yervoy&nbsp;compared to 20.6 months with the investigator&#8217;s choice of lenvatinib or sorafenib.
The OS benefit was observed across clinically relevant patient subgroups. The trial also showed an overall response rate (ORR) of 36.1% compared to 13.2% of patients treated with lenvatinib or sorafenib and a deeper response with&nbsp;Opdivo&nbsp;plus&nbsp;Yervoy.
The safety profile for the combination of Opdivo plus Yervoy remained consistent with previously reported data and was manageable with established protocols, with no new safety signals identified.
In August 2024, the U.S. FDA <a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.bms.com%2Fnews%2Fdetails%2F2024%2FBristol-Myers-Squibb-Receives-U.S.-Food-and-Drug-Administration-sBLA-Acceptance-for-First-Line-Treatment-of-Unresectable-Hepatocellular-Carcinoma%2Fdefault.aspx&amp;esheet=54220615&amp;newsitemid=20250306548758&amp;lan=en-US&amp;anchor=accepted+the+Company%27s+supplemental+Biologics+License+Application&amp;index=3&amp;md5=2b15074d7f5cda1d8e3db3a5f1804863" rel="noreferrer noopener">accepted the company&#8217;s supplemental Biologics License Application</a> for Opdivo plus Yervoy as a potential first-line treatment option for adult patients with unresectable HCC and assigned a Prescription Drug User Fee Act goal date of April 21, 2025.
The combination of&nbsp;Opdivo&nbsp;plus&nbsp;Yervoy&nbsp;was granted accelerated approval by the U.S. FDA in 2020 as a second-line treatment for patients with advanced HCC based on Phase 2 CheckMate -040 trial results.
In February, the FDA accepted the supplemental biologics license application (sBLA) for&nbsp;Bristol Myers Squibb&#8217;s Opdivo plus&nbsp;Yervoy&nbsp;as a potential first-line treatment option for adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient <a target="_blank" href="https://www.benzinga.com/25/02/43919389/bristol-myers-opdivo-plus-yervoy-treatment-goes-under-priority-fda-review-for-colorectal-cancer" rel="noreferrer noopener">colorectal cancer (mCRC)</a>.
The FDA granted the application Breakthrough Therapy Designation and Priority Review status. It also assigned a Prescription Drug User Fee Act goal date of June 23, 2025.
Price Action: BMY stock is down 0.14% at $60.09 during the premarket session at the last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44189186/venture-global-beats-eps-estimates-announces-18-billion-expansion-at-plaquemines" target="_blank" rel="noreferrer noopener">Venture Global&#8217;s Inaugural Earnings Report: Sales Miss, $18 Billion LNG Expansion At Louisiana And More</a></li>
</ul>

Biotech

Large Cap

Health Care

General

Bristol Myers' Opdivo Plus Yervoy Combo Therapy Secures European Approval For Untreated Liver Cancer Patients

Bristol Myers Squibb Says European Commission Approved Opdivo Plus Yervoy For First-line Treatment Of Adult Patients With Unresectable Or Advanced Hepatocellular Carcinoma

Bristol-Myers Squibb's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) short percent of float has fallen 4.55% since its last report. The company recently reported that it has 25.59 million shares sold short, which is 1.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.91 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Bristol-Myers Squibb Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741293035_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Bristol-Myers Squibb has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Bristol-Myers Squibb's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 4.06%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Bristol-Myers Squibb?

Fulcrum Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) received written notice from MyoKardia, Inc. for the termination of the collaboration and license agreement <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">dated July 20, 2020</a>.
Under the agreement, Fulcrum had granted MyoKardia an exclusive worldwide license to discover, develop, and commercialize novel targeted therapies for genetic cardiomyopathies.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40837254/fulcrum-therapeutics-suspends-rare-muscular-disease-candidate-after-disappointing-data-from-pivot" rel="noreferrer noopener">Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial</a>
Under the agreement, under a mutually agreed research plan, Fulcrum agreed to perform assay screening and related research activities to identify and validate up to a specified number of potential cardiomyopathy gene targets for further research, development, manufacture, and commercialization by MyoKardia.
MyoKardia paid Fulcrum $10.0 million upfront and $2.5 million in prepaid research funding. It also agreed to reimburse Fulcrum for the costs of research activities not covered by the prepaid research funding up to a maximum of the total research funding.
Upon the achievement of specified milestones, Fulcrum would have been entitled to preclinical milestone payments, development milestone payments and sales-based milestone payments of up to $298.5 million in the aggregate per target for certain identified targets, and of up to $150.0 million in the aggregate per target for certain other identified targets.
Fulcrum achieved a $2.5 million specified preclinical milestone. MyoKardia also agreed to pay Fulcrum tiered royalties ranging from a mid-single-digit percentage to a low double-digit percentage.
In 2020, Bristol Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) acquired <a target="_blank" href="https://www.benzinga.com/general/biotech/21/05/21147817/bristol-myers-unveils-more-mavacamten-data-to-backup-case-for-heart-drug" rel="noreferrer noopener">MyoKardia for $13.1 billion</a>.
As per the SEC <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1680581/000095017025032355/fulc-20250226.htm" rel="noreferrer noopener">filing</a>, the termination will become effective on June 26, 2025.
Price Action: FULC stock is up 1.38% at $3.32 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/03/44144092/why-is-hims-hers-health-stock-trading-lower-on-wednesday" target="_blank" rel="noreferrer noopener">Why Is Hims &amp; Hers Health Stock Trading Lower On Wednesday?</a></li>
</ul>

Contracts

FULC

Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal

<ul>
<li>Under this agreement, Fulcrum had granted MyoKardia exclusive rights to develop products targeting specific genes linked to certain genetic heart conditions.&nbsp;</li>
<li>Until the termination of the agreement, the parties will continue to perform their respective obligations under the agreement. As of the termination date, the agreement will be terminated in its entirety, following which Fulcrum will not be entitled to receive any further milestone payments, royalties, or research activity cost reimbursement.</li>
<li>Under the agreement, pursuant to a mutually agreed research plan, Fulcrum agreed to perform assay screening and related research activities to identify and validate up to a specified number of potential cardiomyopathy gene targets for further research, development, manufacture and commercialization by MyoKardia.</li>
<li>Under the agreement, MyoKardia made a $10.0 million upfront payment and a $2.5 million payment as prepaid research funding to Fulcrum. MyoKardia also agreed to reimburse Fulcrum for the costs of the research activities not covered by the prepaid research funding, up to a maximum amount of total research funding (including the prepaid research funding). Upon the achievement of specified milestones, Fulcrum would have been entitled to preclinical milestone payments, development milestone payments and sales-based milestone payments of up to $298.5 million in the aggregate per target for certain identified targets, and of up to $150.0 million in the aggregate per target for certain other identified targets. Fulcrum achieved a $2.5 million specified preclinical milestone. MyoKardia also agreed to pay Fulcrum tiered royalties ranging from a mid single-digit percentage to a low double-digit percentage based on MyoKardia's, and any of its affiliates' and sublicensees', annual worldwide net sales of products under the agreement directed against any identified target. The royalties were payable on a product-by-product basis during a specified royalty term, and could have been reduced in specified circumstances.</li>
</ul>

Fulcrum Therapeutics Has Received Written Notice From Bristol Myers Squibb-Acquired MyoKardia To End Their Collaboration And License Agreement, Originally Signed On July 20, 2020, The Termination Will Officially Take Effect On June 26, 2025-8K

<ul>
<li>Ongoing strategic partnership advances joint pipeline in neurodegeneration research</li>
<li>Evotec receives a $20 million payment to further progress research</li>
</ul>

Evotec Advances Neuroscience Partnership With Bristol Myers Squibb, Secures $20M For Neurodegeneration Research

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$42.00</td>
<td>$33.4K</td>
<td>6.5K</td>
<td>5.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/28/25</td>
<td>$27.00</td>
<td>$47.3K</td>
<td>322</td>
<td>2.3K</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$65.00</td>
<td>$28.0K</td>
<td>11.9K</td>
<td>672</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$87.00</td>
<td>$30.2K</td>
<td>6</td>
<td>500</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$43.00</td>
<td>$41.2K</td>
<td>5.7K</td>
<td>81</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$230.00</td>
<td>$56.9K</td>
<td>1.9K</td>
<td>80</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$915.00</td>
<td>$32.2K</td>
<td>177</td>
<td>66</td>
</tr>
<tr>
<td>BBIO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$30.00</td>
<td>$34.0K</td>
<td>6.0K</td>
<td>50</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$520.00</td>
<td>$58.0K</td>
<td>962</td>
<td>40</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$310.00</td>
<td>$53.0K</td>
<td>38</td>
<td>19</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a put option trade that happens to be bullish, expiring in 22 day(s) on March 21, 2025. This event was a transfer of 100 contract(s) at a $42.00 strike. The total cost received by the writing party (or parties) was $33.4K, with a price of $334.0 per contract. There were 6534 open contracts at this strike prior to today, and today 5139 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bearish sentiment. It expires in 29 day(s) on March 28, 2025. Parties traded 720 contract(s) at a $27.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $47.3K, with a price of $65.0 per contract. There were 322 open contracts at this strike prior to today, and today 2378 contract(s) were bought and sold. 
• For SWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>), we notice a call option sweep that happens to be bullish, expiring in 22 day(s) on March 21, 2025. This event was a transfer of 100 contract(s) at a $65.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $280.0 per contract. There were 11949 open contracts at this strike prior to today, and today 672 contract(s) were bought and sold. 
• For DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we notice a put option trade that happens to be bearish, expiring in 22 day(s) on March 21, 2025. This event was a transfer of 144 contract(s) at a $87.00 strike. The total cost received by the writing party (or parties) was $30.2K, with a price of $210.0 per contract. There were 6 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a call option trade that happens to be bullish, expiring in 323 day(s) on January 16, 2026. This event was a transfer of 25 contract(s) at a $43.00 strike. The total cost received by the writing party (or parties) was $41.2K, with a price of $1650.0 per contract. There were 5751 open contracts at this strike prior to today, and today 81 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bearish sentiment. It expires in 323 day(s) on January 16, 2026. Parties traded 67 contract(s) at a $230.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $56.9K, with a price of $850.0 per contract. There were 1944 open contracts at this strike prior to today, and today 80 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with neutral sentiment. It expires in 8 day(s) on March 7, 2025. Parties traded 15 contract(s) at a $915.00 strike. The total cost received by the writing party (or parties) was $32.2K, with a price of $2150.0 per contract. There were 177 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
• Regarding BBIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>), we observe a call option trade with bullish sentiment. It expires in 78 day(s) on May 16, 2025. Parties traded 50 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $680.0 per contract. There were 6077 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option trade with bearish sentiment. It expires in 113 day(s) on June 20, 2025. Parties traded 10 contract(s) at a $520.00 strike. The total cost received by the writing party (or parties) was $58.0K, with a price of $5800.0 per contract. There were 962 open contracts at this strike prior to today, and today 40 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option trade that happens to be bullish, expiring in 204 day(s) on September 19, 2025. This event was a transfer of 19 contract(s) at a $310.00 strike. The total cost received by the writing party (or parties) was $53.0K, with a price of $2790.0 per contract. There were 38 open contracts at this strike prior to today, and today 19 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

BBIO

DXCM

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MRNA

SWTX

10 Health Care Stocks Whale Activity In Today's Session

On Monday, the FDA accepted the supplemental biologics license application (sBLA) for Bristol Myers Squibb&nbsp;&amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo&nbsp;(nivolumab) plus&nbsp;Yervoy&nbsp;(ipilimumab) as a potential first-line treatment option for adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43908522/u-s-food-and-drug-administration-accepts-bristol-myers-squibbs-supplemental-biologics-license-appl" rel="noreferrer noopener">colorectal cancer (mCRC)</a>.
The FDA granted the application Breakthrough Therapy Designation and Priority Review status. It also assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43597173/whats-going-on-with-bristol-myers-squibb-stock-on-monday" rel="noreferrer noopener">What&#8217;s Going On With Bristol Myers Squibb Stock On Monday?</a>
The application was based on results from the three-arm Phase 3 CheckMate -8HW study, which demonstrated that Opdivo plus Yervoy&nbsp;met the dual primary endpoints of progression-free survival (PFS) compared to the investigator&#8217;s choice of chemotherapy in the first-line setting and compared to&nbsp;Opdivo&nbsp;monotherapy across all lines of therapy.
Opdivo&nbsp;plus&nbsp;Yervoy&nbsp;received FDA approval in July 2018 for adult and pediatric patients 12 years and older with MSI-H or dMMR mCRC that have progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.&nbsp;
Opdivo&nbsp;plus&nbsp;Yervoy&nbsp;was also approved in December 2024 in the&nbsp;European Union&nbsp;for the first-line treatment of adult patients with MSI-H or dMMR unresectable or mCRC and in October 2024 for the same indication by the China National Medical Products Administration.
Last week, Bristol Myers announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study. The trial evaluated Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable non-small <a href="https://www.benzinga.com/25/02/43830315/bristol-myers-lead-cancer-drug-opdivo-in-combination-with-chemo-shows-improved-overall-survival-in-certain-patients-with-lung-cancer" target="_blank" rel="noreferrer noopener">cell lung cancer (NSCLC)</a>.
The results showed a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint, compared to neoadjuvant chemotherapy alone.
Price Action: Bristol Myers stock is up 2.97% at $57.49 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/02/43911011/raytheon-elcan-secures-key-contract-to-supply-dual-role-sights-to-danish-armed-forces" target="_blank" rel="noreferrer noopener">Raytheon ELCAN Secures Key Contract To Supply Dual-Role Sights To Danish Armed Forces</a></li>
</ul>
Image: Courtesy of Bristol Myers Squibb

Movers

Bristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review

WIIM

Bristol-Myers Squibb shares are trading higher after the company announced its Opdivo-Yervoy combo has received an FDA Priority Review designation for metastatic colorectal cancer

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54212121&amp;newsitemid=20250221644802&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=a5247aabe0a54610653d2c12bfc1f17c">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for Opdivo&#xAE; (nivolumab) plus Yervoy&#xAE;(ipilimumab) as a potential first-line treatment option for adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (mCRC). The FDA granted the application Breakthrough Therapy Designation and Priority Review status and assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025.

Government

Regulations

Bristol Myers Squibb's Opdivo-Yervoy Combo Gets FDA Priority Review for Metastatic Colorectal Cancer

On Friday, Exelixis, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) authorized repurchasing up to an additional $500 million of the company&#8217;s common stock before <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43868849/exelixis-announces-a-newly-authorized-500-million-stock-repurchase-program" rel="noreferrer noopener">December 31, 2025</a>.
Exelixis plans to complete the $500 million stock repurchase program, announced in August 2024, in the second quarter of 2025 and commence stock repurchases under the newly authorized stock repurchase program thereafter.
As of the end of fiscal year 2024, Exelixis has returned over $1.2 billion to shareholders through these programs.
Earlier this month, Exelixis reported fourth-quarter adjusted EPS of 55 cents, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 43 cents</a>. The cancer-focused company reported sales of $566.75 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43640071/exelixis-announces-fourth-quarter-and-fiscal-year-2024-financial-results-and-provides-corporate-up" rel="noreferrer noopener">consensus of $563.42 million</a>.
Exelixis reaffirmed its 2025 sales guidance of $2.15 billion-$2.25 billion versus consensus of $2.24 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42488323/drug-price-hikes-unsupported-by-evidence-cost-us-815-million-icer-report" rel="noreferrer noopener">Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report</a>
Recently, Exelixis announced the final results from the phase 3 CheckMate -9ER pivotal trial evaluating Cabometyx&nbsp;(cabozantinib) in combination with Bristol-Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo&nbsp;(nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC).
After more than five years of follow-up, the findings demonstrated that the efficacy benefits of Cabometyx&nbsp;in combination with Opdivo were sustained long-term.
At a median follow-up of 67.6 months, Cabometyx, in combination with Opdivo, improved progression-free survival and overall survival compared with Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Sutent (sunitinib) in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43756537/exelixis-announces-final-five-year-follow-up-results-from-checkmate-9er-trial-evaluating-cabometyx" rel="noreferrer noopener">intent-to-treat population</a>.
A subgroup analysis by the International Metastatic RCC Database Consortium (IMDC) risk showed PFS and objective response rates favored Cabometyx in combination with Opdivo versus sunitinib regardless of the IMDC risk group.
In January, Exelixis announced that its supplemental New Drug Application (sNDA) for cabozantinib for adults with previously treated advanced pancreatic neuroendocrine and extra-pancreatic tumors will no longer be discussed at the FDA&#8217;s Oncologic Drugs Advisory Committee meeting. The sNDA remains under consideration by the FDA and has a Prescription Drug User Fee Act action <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42896345/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-" rel="noreferrer noopener">date of April 3</a>.
Price Action: EXEL stock is up 3.42% at $36.29 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43888652/trump-medias-strategic-fund-set-to-fuel-mergers-and-acquisitions" target="_blank" rel="noreferrer noopener">Trump Media&#8217;s Strategic Fund Set To Fuel Mergers And Acquisitions: Details</a></li>
</ul>

Buybacks

EXEL

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program to Bristol Myers Squibb.&nbsp;Closing of the agreement has been completed and BioArctic will receive an upfront payment of USD 100 million.

BRCTF

BioArctic And Bristol Myers Squibb Finalize $100M Licensing Deal For PyroGlu-Aβ Antibody Program After U.S. Antitrust Clearance

On Wednesday, Bristol Myers Squibb&nbsp;&amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated&nbsp;Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable non-small <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43808682/bristol-myers-squibb-announces-opdivo-plus-chemotherapy-as-the-first-and-only-neoadjuvant-only-imm" rel="noreferrer noopener">cell lung cancer (NSCLC)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43774882/donald-trumps-tax-cut-could-add-46-trillion-to-deficit-says-robert-reich-emphasizing-48-billion-relief-for-top-100-us-firms-via-corporate-tax-cuts" rel="noreferrer noopener">Trump&#8217;s Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich</a>
The results showed a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint, compared to neoadjuvant chemotherapy alone.
The results build on the previously reported primary endpoints of event-free survival (EFS) and pathological complete response (pCR), which also met statistical significance.
The safety profile of&nbsp;Opdivo&nbsp;in combination with chemotherapy was consistent with previously reported studies, with no new safety signals observed.
&#8220;The final analysis of overall survival in the CheckMate -816 study underscores the potential of&nbsp;Opdivo&nbsp;in combination with chemotherapy to provide a meaningful survival benefit for patients with resectable NSCLC,&#8221; said Dana Walker, vice president, global program lead, late development, oncology, Bristol Myers Squibb. &#8220;This is the first and only Phase 3 study of a neoadjuvant-only immuno-oncology therapy to show a statistically significant benefit in patients with resectable NSCLC.&#8221;
In October, the FDA approved&nbsp;Bristol Myers&#8217; Opdivo for resectable NSCLC and no known epidermal growth factor&nbsp;receptor mutations or anaplastic lymphoma kinase (ALK) rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy,&nbsp;followed by single-agent&nbsp;Opdivo&nbsp;as adjuvant&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41184042/bristol-myers-10b-cancer-drug-opdivo-scores-expanded-use-fda-approval-for-lung-cancer-in-pre-and-" rel="noreferrer noopener">treatment after surgery</a>.
Last week, Bristol Myers released topline data from its Phase 2 TRANSCEND FL trial of&nbsp;Breyanzi&nbsp;(lisocabtagene maraleucel) for relapsed or refractory indolent B-cell&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43597173/whats-going-on-with-bristol-myers-squibb-stock-on-monday" rel="noreferrer noopener">non-Hodgkin lymphoma</a>.
The study met its primary endpoint in the marginal zone lymphoma (MZL) cohort and Breyanzi&nbsp;demonstrated a statistically significant and clinically meaningful overall response rate (ORR) in these patients. It also met the key secondary endpoint of complete response rate (CRR).
Price Action: BMY stock closed higher by 1.01% to $54.98 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43817229/nisun-international-partners-with-gold-of-china-aiming-30-50-million-gold-market-expansion-in-2025" target="_blank" rel="noreferrer noopener">Nisun Partners With Gold Of China To Tap Booming Market: Details</a></li>
</ul>
Photo via Shutterstock

Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Organon &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>)</h3>
<ul>
<li>Dividend Yield: 7.24%</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $17 to $16 on Feb. 14. This analyst has an accuracy rate of 68%.</li>
<li>Piper Sandler analyst David Amsellem maintained an Overweight rating and raised the price target from $22 to $24 on April 29, 2024. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: On Feb. 13, Organon reported better-than-expected fourth-quarter adjusted EPS results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021925&amp;t=be2bearmibe3na1">OGN news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021925&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="842" height="767" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080423/image-163.png" alt="" class="wp-image-788843" style="width:573px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080423/image-163.png 842w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080423/image-163-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080423/image-163-768x700.png 768w" sizes="(max-width: 842px) 100vw, 842px" /></a></figure>
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul>
<li>Dividend Yield: 6.73%</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating with a price target of $33 on Feb. 10, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and cut the price target from $30 to $29 on Jan. 28, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On Feb. 13, Pfizer reported Phase 3 TALAPRO-2 study results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021925&amp;t=be2bearmibe3na1">PFE news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021925&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080512/image-164.png" alt="" class="wp-image-788845" style="width:676px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080512/image-164.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080512/image-164-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080512/image-164-768x704.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.56%</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and boosted the price target from $60 to $65 on Jan. 28, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On Feb. 19, Bristol Myers Squibb announced the final analysis of overall survival from the Phase 3 Checkmate -816 study, which evaluated Opdivo (Nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable (Tumors ≥ 4 cm or node positive) non-small cell lung cancer.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021925&amp;t=be2bearmibe3na1">BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021925&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080554/image-165.png" alt="" class="wp-image-788846" style="width:696px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080554/image-165.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080554/image-165-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080554/image-165-768x713.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Dividends

Price Target

Analyst Ratings

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

Bristol Myers Squibb Announced The Final Analysis Of Overall Survival From The Phase 3 Checkmate -816 Study, Which Evaluated Opdivo (Nivolumab) In Combination With Platinum-doublet Chemotherapy As A Neoadjuvant Treatment For Adult Patients With Resectable (Tumors ≥ 4 Cm Or Node Positive) Non-small Cell Lung Cancer

Former U.S. Secretary of Labor Robert Reich has called out the tax reduction plans of the Donald Trump-led administration in an X post, terming them as an &#8220;absolutely shameless giveaway,&#8221; that could shoot up the deficit by $4.6 trillion.
What Happened: The possible tax cuts for rich individuals and lower corporate tax rates are likely to widen the U.S. trade deficit, which the Trump 2.0 administration would most likely fund from the tariffs imposed on its trading partners.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Trump wants to extend his tax cuts for rich individuals, which would add $4.6T to the deficit. But he wants to go even further, cutting the corporate tax rate to 15%. It&#39;s yet another absolutely shameless giveaway. <a href="https://t.co/mkAWOFkkUd">pic.twitter.com/mkAWOFkkUd</a>
&mdash; Robert Reich (@RBReich) <a href="https://twitter.com/RBReich/status/1891623719304339516?ref_src=twsrc%5Etfw">February 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The data from the Center For American Progress Action Fund or CAPAF shows that cutting the corporate tax rate down to 15% would save all sectors and companies billions of dollars in tax.
<ul>
<li>Top 100 U.S. Companies: Can expect a total annual tax cut of $48 billion despite reporting $1.1 trillion in profits in their 2023 annual report.</li>
</ul>
<ul>
<li>Top 10 U.S. Companies: Reported more than $520 billion in profits according to their 2023 annual report can expect an annual tax cut of $23 billion. These include firms like Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Comcast Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), and JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>).</li>
</ul>
<ul>
<li>Oil: The five largest U.S. oil companies, including Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>), Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>), and Valero Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) will receive an estimated $2.2 billion annual tax cut, despite over $80 billion in profits.</li>
</ul>
<ul>
<li>Pharma: The five largest U.S. drug makers, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) will receive an estimated $3.1 billion annual tax cut, despite over $50 billion in profits.</li>
</ul>
<ul>
<li>Banking: The five largest Wall Street banks, JPMorgan Chase, Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) and Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) will receive an estimated $4.1 billion annual tax cut, despite nearly $113 billion in profits.</li>
</ul>
<ul>
<li>Grocery: The five largest grocery companies, Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>), Costco Wholesale Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>), Albertsons Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>), Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) and Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) will receive an estimated $1.7 billion annual tax cut, despite over $29 billion in profits.</li>
</ul>
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43763438/trump-acting-like-a-mafia-don-says-this-economist-as-uncertainty-mounts-businesses-hold-back-in-fear-of-unforeseen-economic-shifts">Trump &#8216;Acting Like A Mafia Don,&#8217; Says This Economist As Uncertainty Mounts, Businesses Hold Back In Fear Of Unforeseen Economic Shifts</a>
Why It Matters: Trump has threatened all its trading partners with &#8220;reciprocal tariffs,&#8221; while already having implemented 25% on steel and aluminum imports.
According to economists like Craig Shapiro, who is a macro strategist at the Bear Traps Report, tariffs are the "<a href="https://www.benzinga.com/25/02/43587245/tariffs-are-the-only-way-to-fund-tax-cuts-without-deficit-expansion-argues-expert-as-it-takes-center-stage-in-donald-trumps-economic-plan">only way</a>" to fund tax cuts without expanding the federal deficit. 
Shapiro likened Trump&#8217;s governance to that of a &#8220;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43763438/trump-acting-like-a-mafia-don-says-this-economist-as-uncertainty-mounts-businesses-hold-back-in-fear-of-unforeseen-economic-shifts">Mafia Don</a>,&#8221; saying businesses are now uncertain about the economy&#8217;s direction. He noted fading &#8220;initial euphoria&#8221; and a &#8220;wait-and-see&#8221; approach from business leaders due to unclear policies, tariffs, trade agreement uncertainty, and fluctuating government spending. &#8211;
Price Action: On Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) which track the S&amp;P 500 and Nasdaq 100 indices, closed mixed. SPY fell 0.0049% to a value of $609.7, and QQQ was up by 0.42% to end at a value of $538.15, according to Benzinga Pro data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43773441/ahead-of-gamestops-bitcoin-purchase-plans-blackrock-morgan-stanley-goldman-sachs-and-other-billion-dollar-funds-load-up-on-gme-stock-in-q4">Ahead Of GameStop&#8217;s Bitcoin Purchase Plans, BlackRock, Morgan Stanley, Goldman Sachs, And Other Billion Dollar Funds Load Up On GME Stock In Q4</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Macro Notification

Economics

CMCSA

COST

Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile
Following five years of continuous Sotyktu treatment, clinical response was maintained in nearly half of patients for Psoriasis Area and Severity Index (PASI) 90 in the POETYK PSO long-term extension trial
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com&amp;esheet=54207062&amp;newsitemid=20250216956334&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=d312e4385e5fe1fc51c3a0e3b138ed8e">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. The safety profile of Sotyktu remained consistent through five years with more than 5,000 patient-years of exposure in the trial, with no new safety signals identified. In patients who were treated continuously with Sotyktu, clinical response rates were maintained from Year 1 to Year 5, including Psoriasis Area and Severity Index (PASI) 75, PASI 90 and static Physician's Global Assessment (sPGA) 0/1 (clear/almost clear).
These data were presented at the Winter Clinical Dermatology Conference – Hawaii (WCH) in Big Island, Waikoloa Village, HI taking place February 14-19, 2025.

Bristol Myers Squibb Says New 5-Year Sotyktu Data Show Consistent Safety And Durable Response Rates In Moderate-To-Severe Plaque Psoriasis; No New Safety Signals Observed At Year 5 In The POETYK PSO Long-Term Extension Trial, Consistent With The Established Sotyktu Safety Profile

Bristol Myers Squibb Phase 3 RELATIVITY-098 Trial Of Opdualag Did Not Meet Primary endpoint

Whales with a lot of money to spend have taken a noticeably bullish stance on Bristol-Myers Squibb.
Looking at options history for Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 30% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $160,750 and 6, calls, for a total amount of $225,501.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $60.0 for Bristol-Myers Squibb, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Bristol-Myers Squibb stands at 1844.57, with a total volume reaching 10,340.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Bristol-Myers Squibb, situated within the strike price corridor from $50.0 to $60.0, throughout the last 30 days.
<h3>Bristol-Myers Squibb Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739386827_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.82</td>
<td>$1.74</td>
<td>$1.74</td>
<td>$60.00</td>
<td>$82.6K</td>
<td>3.2K</td>
<td>537</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/28/25</td>
<td>$0.6</td>
<td>$0.56</td>
<td>$0.6</td>
<td>$53.00</td>
<td>$52.3K</td>
<td>246</td>
<td>969</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.94</td>
<td>$1.85</td>
<td>$1.85</td>
<td>$52.50</td>
<td>$44.0K</td>
<td>4.1K</td>
<td>239</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/28/25</td>
<td>$0.61</td>
<td>$0.55</td>
<td>$0.6</td>
<td>$53.00</td>
<td>$38.2K</td>
<td>246</td>
<td>969</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$0.28</td>
<td>$0.27</td>
<td>$0.28</td>
<td>$57.00</td>
<td>$31.5K</td>
<td>1.9K</td>
<td>3.4K</td>
</tr>
</tbody>
</table>

<h3>About Bristol-Myers Squibb</h3>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
<h3>Present Market Standing of Bristol-Myers Squibb</h3>
<ul>
<li>With a trading volume of 4,560,473, the price of BMY is down by -0.38%, reaching $55.73.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 71 days from now.</li>
</ul>
<h3>Expert Opinions on Bristol-Myers Squibb</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $60.666666666666664.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald persists with their Neutral rating on Bristol-Myers Squibb, maintaining a target price of $55. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Bristol-Myers Squibb with a target price of $65. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Bristol-Myers Squibb, which currently sits at a price target of $62. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bristol-Myers Squibb with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Bristol-Myers Squibb Unusual Options Activity

Press Releases

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer

BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Bristol Myers Squibb Announces Dividend

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Bristol-Myers Squibb

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌